leadf
logo-loader
viewAntibe Therapeutics Inc

Antibe Therapeutics closes $28.75 million offering ahead of planned Phase 3 trial of ATB-346

Antibe is developing ATB-346 to work as an alternative to nonsteroidal anti-inflammatory drugs, or NSAIDs

Antibe Therapeutics Inc -
The offering included 62.5 million units priced at C$0.40 plus the full exercise of an overallotment option of 9.375 million units

Antibe Therapeutics Inc (CVE:ATE) (OTCMKTS:ATBPF) closed a C$28.75 million financing ahead of its planned Phase 3 trial of its lead drug ATB-346, a novel anti-inflammatory medecine.

The offering included 62.5 million units priced at C$0.40 plus the full exercise of an overallotment option of 9.375 million units for total gross proceeds of $28.75 million.

Underwriters Bloom Burton Securities Inc led the offering along with Echelon Wealth Partners Inc, Paradigm Capital Inc, Raymond James Ltd, Stifel GMP and Industrial Alliance Securities Inc.  

READ: Antibe Therapeutics unveils positive topline results from Phase 2B clinical trial of ATB-346 for osteoarthritis pain

Each unit was comprised of one share of Antibe and one-third of one warrant exercisable at C$0.60 per share for a two-year period. The units were offered and sold by way of a short form prospectus filed in each of the provinces of Alberta, British Columbia, Manitoba, Ontario, and Saskatchewan.

Antibe paid the underwriters a cash commission equal to 7% of the gross proceeds raised in the offering and granted them non-transferrable broker warrants equal to 7% of the number of units sold. The units are exercisable at any time prior to June 30, 2022 at an exercise price equal to the offering price.

Toronto-based Antibe is developing ATB-346 to work as an alternative to nonsteroidal anti-inflammatory drugs, or NSAIDs. The drug is a naproxen-derivative that has been shown to deliver pain relief with significantly less gastrointestinal damage than typical NSAID usage.

The pharmaceutical firm also plans to use proceeds from the offering to advance other drugs in its pipeline, including ATB-352 for post-operative pain. Funds will also be used for working capital and general corporate purposes.

Quick facts: Antibe Therapeutics Inc

Price: - -

TSX-V:ATE
Market: TSX-V
Market Cap: -
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Antibe Therapeutics Inc named herein, including the promotion by the Company of Antibe Therapeutics Inc in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Antibe Therapeutics releases data from company’s Phase II placebo-controlled...

Antibe Therapeutics (CVE: ATE) CEO Dan Legault joined Steve Darling from Proactive Vancouver with new results from the company’s analysis of primary and secondary data from ATB-346’s recent placebo-controlled efficacy trial. Legault shares the data with Proactive and he also maps out the...

on 08/12/2020

2 min read